Navigation Links
Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists
Date:1/21/2008

SWEDESBORO, N.J., Jan. 21 /PRNewswire/ -- Wedgewood Pharmacy has announced that it will continue to provide Avastin(R) (Bevacizumab) to retinal specialists and ophthalmologists who request it for their patients. The announcement responds to Avastin's manufacturer, Genentech's, decision (http://www.lucentis.com/lucentis/pdf/announcement.pdf) to stop supplying Avastin directly to compounding pharmacies as of January 1.

Avastin is commonly administered by retinal specialists and ophthalmologists to treat age-related wet macular-degeneration, a leading cause of blindness in the elderly. Although regulators haven't authorized Avastin's use against eye disease, it is chemically similar to Genentech's new product, Lucentis(R), which is about 50 times as costly as Avastin. On prescriptive authority of physicians, compounding pharmacies prepare, under sterile laboratory conditions, a once-monthly dose of the drug for use in the eye that costs about $40.

At Wedgewood, technicians trained in aseptic technique prepare Avastin 25mg/ml in individual syringes in a Class-1000 clean room under a Class-100 laminar-flow hood to assure sterility and quality.

"Many retinal specialists consider the Avastin treatment option as an indispensable part of their practices," said George Malmberg, RPH, FACA, FACVP the pharmacist president and CEO of Wedgewood Pharmacy. "We will continue to meet the critical and ongoing need for Avastin in ophthalmologic practice. Unlike other firms, we do not require that our customers make a long-term contractual agreement to purchase this vital medicine from us."

Avastin is an FDA-approved drug that is used in the treatment of metastatic colorectal cancer. Based on the pioneering work of Dr. Philip Rosenfeld, a professor of Ophthalmology at the world-renowned Bascom Palmer Eye Institute at the University of Miami, Miller School of Medicine, Avas
'/>"/>

SOURCE Wedgewood Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
2. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
3. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
4. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
5. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
6. Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008
7. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
8. Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits
9. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)..., SPRING VALLEY, Calif., Nov. 6 ...awarded a Small Business Innovative Research (SBIR...ch and Material command. Under terms of the agreem...ents (ASRs) for the diagnosis of Dengue virus. ...hat represents a major threat to military forces d...
(Date:11/5/2009)..., TRANSPORTATION -- Gone hybrid . . . , Fuel ...biles are now posted at the www.fueleconomy.gov ...loped and maintains for the U.S. Department of Ene...Nine of the top 10 vehicles on the best fuel econo...ius (51 MPG city; 48 highway). "This list proves t...
(Date:11/5/2009)..., SAN DIEGO, Nov. 5 Im...ed today that William Spencer, President and CEO o...ry at the 2nd annual LD MICRO Conference on Thursd...et in Los Angeles. ,, About LD MICRO ,, LD M...focuses on finding undervalued companies in the mi...
(Date:11/5/2009)..., LYNBROOK, N.Y., Nov. 5 /PRNewswire-FirstCall/ ...), a biopharmaceutical company developing first-in... its financial results for the third quarter ended...py that, in September of this year, the FDA,s Arth...by a vote of 12-0, the approval of XIAFLEX(TM) for...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
...h 25 InNexus Biotechnology Inc., (OTC Bulletin Bo...om ), a drug development company commercializing t...on its Dynamic Cross Linking (DXL) technology, is ...nto a loan facility with a group of investors for ..., The loan facility, subject to final approval of ...
...sion Inc. ("Encision") (OTC Bulletin Board: ECIA),... technology that is emerging as a standard of care...n agreement with Caldera Medical, Inc. ("Caldera")...,s products include the Desara(R) Sling System for...imated to affect 15 million women in the U.S. Enc...
...FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics"...mpletion of patient enrolment in its U.K. clinical...avenous administration of REOLYSIN(R) in combinati...dvanced cancers including breast, and head and nec...ono of The Royal Marsden NHS Foundation Trust and ...
Other Biology Technology:InNexus Biotechnology Announces a Loan Facility of up to USD$2.5 Million 2Encision Enters Into Sales Representation Agreement With Caldera Medical 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:11/9/2009)...wet ethanol production method that begins by soaki... in more gallons of ethanol and more usable co-pro...their buck by about 20 percent. , "The conventi...t other than distillers dried grains with soluble,...ersity of Illinois Agricultural Engineer Esha Khul...
(Date:11/9/2009)...hildren with cancer, the hopeful news is that pedi...cades. Among the bad newstreatments that enable su...ed with cancer who have reached puberty currently ...efore undergoing cancer treatment, they may have t...unger boys, however, do not produce sperm, althoug...
(Date:11/9/2009)...a. The U.S. Department of Energy (DOE) has announ...abama at Birmingham (UAB) School of Engineering on...s emissions through the capture and permanent safe...). The project is in collaboration with Southern C...unded by the DOE through the 2009 American Recover...
Breaking Biology News(10 mins):Wet ethanol production process yields more ethanol and more co-products 2For young boys with cancer, testicular tissue banking may be option to preserve fertility 2For young boys with cancer, testicular tissue banking may be option to preserve fertility 3UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 1Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 2Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 3Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 4New Research Shows 3A Neurofeedback is an Evidence Based Treatment for ADHD 4729 1New Research Shows 3A Neurofeedback is an Evidence Based Treatment for ADHD 4729 2Study demonstrates the anti inflammatory properties of pine bark extract 51856 1Study demonstrates the anti inflammatory properties of pine bark extract 51856 2
... first evidence that a group of proteins called ph...he nervous system, has been shown in fruit flies a...rnia, San Diego (UCSD) School of Medicine, in coll...a Jolla, California. The phosphatases are required...ncing expression of neuronal genes in non-nervous ...
...of 20 April, the Ministry of Health in Angola has ...Of these cases, 244 were fatal. In Uige Province, ...ases, of which 233 have been fatal, were reported ...e international response to the outbreak in Angola... Marburg haemorrhagic fever, and the conditions in...
...ng genetically altered zebrafish that glow in the ... new tools that shed light upon biological clock c...f biology and biochemistry at UH, and Maki Kaneko,...ty of California-San Diego, presented their findin...of Circadian Gene Expression in Transgenic Zebrafi...
Other Biology News:Marburg haemorrhagic fever in Angola update 2Marburg haemorrhagic fever in Angola update 3Glow-in-the-dark zebrafish at UH hold keys to biological clocks 2Glow-in-the-dark zebrafish at UH hold keys to biological clocks 3
MagCellect Rat CD4+ T Cell Isolation Kit from R&D Systems
Rabbit Anti-Human OLFM1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Rabbit Anti-QUINOLINIC ACID Polyclonal Antibody, Unconjugated from AbD Serotec
Coverslips for Microarrays from GE Healthcare, formerly Amersham Biosciences
Biology Products: